Oruka Therapeutics, Inc.
$60.67+5.51%(+$3.17)
TickerSpark Score
63/100
50
Valuation
20
Profitability
60
Growth
84
Health
100
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORKA research report →
52-Week Range62% of range
Low $10.26
Current $60.67
High $91.00
Companywww.orukatx.com
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002.
- CEO
- Lawrence Otto Klein
- IPO
- 1997
- Employees
- 28
- HQ
- Menlo Park, MA, US
Price Chart
+471.28% · this period
Valuation
- Market Cap
- $2.27B
- P/E
- -28.79
- P/S
- 0.00
- P/B
- 6.88
- EV/EBITDA
- -17.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -25.99%
- ROIC
- -27.31%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-105,433,000 · -25.93%
- EPS
- $-2.31 · 53.71%
- Op Income
- $-122,051,000
- FCF YoY
- -52.38%
Performance & Tape
- 52W High
- $91.00
- 52W Low
- $10.26
- 50D MA
- $57.00
- 200D MA
- $33.66
- Beta
- -0.25
- Avg Volume
- 1.40M
Get TickerSpark's AI analysis on ORKA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Agarwal Arjun | other | 2,000 |
| May 18, 26 | Agarwal Arjun | other | 5,833 |
| May 18, 26 | Agarwal Arjun | other | 5,833 |
| May 18, 26 | Agarwal Arjun | sell | 4,190 |
| May 18, 26 | Agarwal Arjun | other | 2,000 |
| May 18, 26 | Agarwal Arjun | sell | 4,600 |
| May 18, 26 | Agarwal Arjun | sell | 800 |
| May 18, 26 | Agarwal Arjun | sell | 700 |
| May 15, 26 | Goncalves Joana | other | 3,500 |
| May 15, 26 | Goncalves Joana | other | 3,500 |
Our ORKA Coverage
We haven't published any research on ORKA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ORKA Report →Similar Companies
PHAT+4.12%
Phathom Pharmaceuticals, Inc.
$11.87
BBOT+1.03%
BridgeBio Oncology Therapeutics Inc.
$8.81
RAPP+3.93%
Rapport Therapeutics, Inc. Common Stock
$35.72
KOD+5.23%
Kodiak Sciences Inc.
$36.22
XNCR+8.74%
Xencor, Inc.
$11.32
NRIX+7.74%
Nurix Therapeutics, Inc.
$16.42
ANAB+0.52%
AnaptysBio, Inc.
$60.08
URGN+6.94%
UroGen Pharma Ltd.
$30.22